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Mutations in PINK1 and Parkin result in autosomal recessive Parkinson’s
disease (PD). Cell culture and in vitro studies have elaborated the PINK1-
dependent regulation of Parkin and defined how this dyad orchestrates
the elimination of damaged mitochondria via mitophagy. PINK1 phosphor-
ylates ubiquitin at serine 65 (Ser65) and Parkin at an equivalent Ser65
residue located within its N-terminal ubiquitin-like domain, resulting in acti-
vation; however, the physiological significance of Parkin Ser65
phosphorylation in vivo in mammals remains unknown. To address this,
we generated a Parkin Ser65Ala (S65A) knock-in mouse model. We observe
endogenous Parkin Ser65 phosphorylation and activation in mature primary
neurons following mitochondrial depolarization and reveal this is disrupted
in ParkinS65A/S65A neurons. Phenotypically, ParkinS65A/S65A mice exhibit
selective motor dysfunction in the absence of any overt neurodegeneration
or alterations in nigrostriatal mitophagy. The clinical relevance of our find-
ings is substantiated by the discovery of homozygous PARKIN (PARK2)
p.S65N mutations in two unrelated patients with PD. Moreover, biochemical
and structural analysis demonstrates that the ParkinS65N/S65N mutant is
pathogenic and cannot be activated by PINK1. Our findings highlight the
central role of Parkin Ser65 phosphorylation in health and disease.1. Introduction
Mutations in genes encoding PTEN-induced kinase 1 (PINK1) (human PARK6)
and the ubiquitin E3 ligase Parkin (human PARK2) are causal for early onset
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phenotypes [1,2]. Patients typically exhibit a motor syndrome
associated with nigrostriatal pathology that can occur in the
absence or the presence of Lewy body inclusions [3]. Under
specific conditions of mitotoxic stress in cultured cells,
PINK1 and Parkin converge in a common signal transduction
pathway to eliminate damaged mitochondria via autophagy,
known as mitophagy [4–6]. Over the last decade, this path-
way has been intensively studied to understand the
mechanisms by which these enzymes regulate mitochondrial
homeostasis [4–6]. In cell culture, PINK1 is activated upon
mitochondrial depolarization that can be induced using mito-
chondrial uncoupling agents, e.g. antimycin A/oligomycin
(A/O). This results in the recruitment and activation of
Parkin at the outer mitochondrial membrane (OMM) [4–6].
PINK1 directly phosphorylates Parkin at a highly conserved
serine 65 (Ser65) residue within its N-terminal ubiquitin-like
domain (Ubl), as well as the equivalent Ser65 residue of
ubiquitin (Ub). Phosphorylation of both Parkin and ubiquitin
is required for maximal activation of Parkin E3 ligase activity
[7–11]. Upon activation, Parkin ubiquitylates multiple
substrates at the OMM leading to both de novo assembly
and elongation of existing ubiquitin chains that are, in
turn, phosphorylated by PINK1. Together, this generates
a feed-forward enhancement of Parkin activation and mito-
chondrial ubiquitylation that heralds the recruitment of
selective autophagy adaptors necessary for the completion
of mitophagy [12–15].
Our present understanding of PINK1-dependent Parkin
activation is largely predicated on in vitro observations and
cell culture studies, which often exploit the over-expression
of exogenous Parkin and/or PINK1 at supra-physiological
levels [4–6]. These include the previous demonstration that
Parkin Ser65 phosphorylation may not be essential for its
complete E3 ligase activity [8,12] or its depolarization-
induced mitochondrial translocation [7,10]. Despite a
concerted body of work in this area from many laboratories,
the physiological significance of Parkin Ser65 phosphoryl-
ation by PINK1 in vivo remains largely enigmatic.
Furthermore, additional substrates for PINK1 have been
widely reported [16] but, to date, it is unknown whether inac-
tivation of PINK1-dependent substrate phosphorylation is
sufficient to recapitulate neurodegeneration in vivo. Models
of germ-line Parkin knockout mice only exhibit mild pheno-
types, with chronic mitotoxicity or extreme stress required
to elicit PD-relevant neurological phenotypes [17–21]. To
test the hypothesis that Parkin Ser65 phosphorylation is criti-
cal for its activation in vivo, we generated a Park2 Ser65Ala
knock-in mouse (ParkinS65A/S65A) and performed an exten-
sive multi-parametric characterization of this model. We
demonstrate that phosphorylation of Ser65 is critical for
endogenous Parkin activation and Ser65-phosphorylated ubi-
quitin (hereafter referred to as phospho-ubiquitin)
accumulation in primary cells, including neurons. Loss of
endogenous Parkin Ser65 phosphorylation and activity
results in selective locomotor impairments, accompanied by
a mild striatal-specific mitochondrial defect in vivo. Further-
more, crossing our ParkinS65A/S65A mice with the recently
described mito-QC mitophagy reporter model [22] revealed
that basal mitophagy in nigrostriatal dopamine neurons pro-
ceeds normally in ParkinS65A/S65A mice, suggesting that the
regulation of basal mitophagy is unaffected by the loss of
Parkin E3 ligase activity in dopaminergic neurons. Thepathophysiological significance of Parkin Ser65 phosphoryl-
ation in mammals is ultimately substantiated by the clinical
discovery of two unrelated patients with relatively early
onset PD harbouring a homozygous PARK2 Ser65Asn (Par-
kinS65N) mutation. Characterization of patient-derived
primary cells demonstrates that the Parkin S65N mutation
is inactive, suggesting that the loss of PINK1-dependent
Parkin Ser65 phosphorylation and subsequent inactivation
in humans is sufficient to cause PD. Taken together, our
data demonstrate that the phosphorylation state of Parkin
at Ser65 is crucial for mitochondrial integrity and human
nigrostriatal function.2. Results
2.1. Endogenous Parkin activation is abolished in
ParkinS65A/S65A knock-in mice
To test the hypothesis that Parkin Ser65 phosphorylation is
central to Parkin activation and neuronal homeostasis in vivo,
we generated a knock-in mouse model in which the codon
encoding Parkin Ser65 was altered by homologous recombina-
tion to alanine to prevent Parkin protein phosphorylation by
PINK1 (figure 1a). Homozygous ParkinS65A/S65A mice were
born at expected Mendelian frequencies and wild-type and
mutant mice were indistinguishable in terms of gross
measures of growth, weight and development (data not
shown).
The expression and stability of the endogenous mutant
ParkinS65A protein in ParkinS65A/S65A mice was comparable
to wild-type mice across all brain regions (olfactory bulb,
cortex, thalamus, striatum, hippocampus, ventral midbrain,
cerebellum, brainstem and spinal cord) and extra-neural tis-
sues (heart, spleen, lung and pancreas) (figure 1b and
electronic supplementary material, figure S1). To assess
how the S65A mutation affects Parkin ubiquitin E3 ligase
activity, we undertook biochemical analysis of endogenous
substrate ubiquitylation in cultured primary neurons. Given
the availability of reliable reagents and building upon our
previous work in this area [11,23], we focused our attention
on the mitochondrial Fe/S domain-containing protein
CISD1, a well-described Parkin substrate, in addition to
monitoring endogenous PINK1-mediated Parkin Ser65 phos-
phorylation. We have previously observed that endogenous
Parkin is expressed at low levels in mouse embryonic fibro-
blasts (MEFs) which limits the robust detection of
endogenous Parkin signalling [23]. However, in primary cor-
tical neuron cultures established from E16.5 mouse embryos
cultured to maturity for 21 days in vitro (DIV), endogenous
Parkin phosphorylation and substrate ubiquitylation are
reliably detectable after combined antimycin A and oligomy-
cin stimulation (to trigger mitochondrial depolarization;
hereafter referred to as A/O) [24]. Upon treatment of
mature (21 DIV) cortical neurons with A/O for three hours
(3 h), we observed complete loss of CISD1 ubiquitylation in
ParkinS65A/S65A neurons compared to wild-type, as measured
by anti-CISD1 immunoblotting (figure 1c). Immunoblot
analysis using anti-phospho-Ser65 Parkin antibodies con-
firmed the loss of Parkin phosphorylation at Ser65 in
mutant neurons (figure 1c). We also assessed endogenous
ubiquitylation status of additional Parkin substrates includ-
ing Mitofusin2, Miro2 and VDAC1; however, we were
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Figure 1. Generation and validation of the ParkinS65A/S65A mouse. (a) Depiction of targeting strategy to generate a constitutive knock-in of Ser65Ala (S65A) point
mutation in the Mus musculus Park2 (Parkin) gene (targeting strategy based on NCBI transcript NM_016694.3). Exon 1 contains the translation initiation codon. The
S65A mutation was introduced into exon 3. The Park2S65A/S65A knock-in (KI) allele was generated following Flp-mediated recombination. (b) Rostro-caudal expression
analysis of Parkin protein expression in the mouse central nervous system (CNS) under basal conditions. Immunoblot analysis of sub-dissected CNS regions from adult
wild-type and ParkinS65A/S65A mice. OB, olfactory bulb; CTX, neocortex; THAL, thalamus; STR, striatum; HC, hippocampus; VM, ventral midbrain; CB, cerebellum; BSt,
brainstem; SPc, spinal cord. (c) Parkin Ser65 phosphorylation is essential for Parkin activation in primary neurons. Mature (21 DIV) primary cortical neuron cultures were
established from wild-type and ParkinS65A/S65A mice, and stimulated for 3 h with a combination of antimycin A (10 mM)/oligomycin (1 mM). Whole-cell extracts were
subjected to SDS-PAGE and immunoblot analysis with anti-Parkin, anti-phospho-Ser65 Parkin, anti-CISD1 and anti-b-III tubulin antibodies.
rsob.royalsocietypublishing.org
Open
Biol.8:180108
3
 on November 12, 2018http://rsob.royalsocietypublishing.org/Downloaded from unable to detect robust signal in neurons in whole-cell lysates
or following HALO-Ubiquilin1 UBA-domain tetramer
(UBAUBQLN1) TUBE-pulldown experiments (electronic sup-
plementary material, figure S2). This may be due to theirlow stoichiometry of ubiquitylation, demonstrated recently
in human neurons by quantitative mass spectrometry [25].
We next asked whether loss of Parkin activity in
ParkinS65A/S65A neurons influenced the PINK1-dependent
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Figure 2. Phospho-ubiquitin levels are diminished in ParkinS65A/S65A mature pri-
mary neurons. Immunoblots showing comparative analysis of phospho-Ser65
ubiquitin levels in mature (21 DIV) primary cortical neuron cultures from the
following groups: ParkinS65A/S65A mice and matched wild-type controls; Pink1
knockout (KO) and wild-type mice and Parkin knockout and wild-type mice. Cul-
tures were stimulated with A/O for 3 h before lysis and membrane enrichment.
Protein extracts were enriched for ubiquitylated substrates by incubating with
ubiquitin-binding resin derived from His-Halo-Ubiquilin UBA-domain tetramer
(HALO-UBAUBQLN1). Enriched lysates were subjected to immunoblotting with
anti-phospho-Ser65 ubiquitin and anti-CISD1 antibodies.
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accumulation. We undertook comparative biochemical ana-
lyses of mature primary neuron cultures established from
homozygous ParkinS65A/S65A, Pink1 knockout and Parkin
knockout mice with their respective corresponding wild-
type littermate controls. Consistent with previous studies in
proliferating cell lines, we observed complete loss of Ser65-
phosphorylated ubiquitin (phospho-ubiquitin) and CISD1
ubiquitylation in Pink1 knockout neurons, as judged by
immunoblotting of HALO-UBAUBQLN1 pulldowns with
anti-phospho-Ser65 ubiquitin and anti-CISD1 antibodies
(figure 2). Strikingly, we did not observe phospho-ubiquitin
accumulation in either ParkinS65A/S65A or Parkin knockout
neurons that were associated with loss of CISD1 substrate
ubiquitylation (figure 2). These data support the Parkin-
dependent feed-forward model of phospho-ubiquitin
accumulation [12,15]. Similar findings were recently reported
in CRISPR/Cas9-mediated S65A mutant human embryonic
stem (ES) cell-derived neurons stimulated with A/O in
which phospho-ubiquitin was not detectable by immuno-
blotting, although the authors were able to detect
phospho-ubiquitin by mass spectrometry [25]. To confirm
this finding in other primary mouse cell types, we exploited a
tractable culture paradigm of mouse primary adult lung fibro-
blast cultures [26]. We stimulated adult primary fibroblast
cultures from ParkinS65A/S65A and Pink1 knockout mice with
the protonophore carbonyl cyanide m-chlorophenyl hydra-
zone (CCCP) for 18 h, which dissipates mitochondrial
membrane potential similar to A/O. As Parkin protein levels
were lower inprimary lung fibroblasts comparedwith neurons,
we performed an additional mitochondrial enrichment step
prior to ubiquitin capture by HALO-UBAUBQLN1 pulldown.
Consistent with our results in neurons, we did not observe
the accumulation of phospho-ubiquitin or CISD1 ubiquityla-
tion in either ParkinS65A/S65A or Pink1 knockout fibroblasts
compared with wild-type cultures (electronic supplementary
material, figure S3). Overall, our data indicate that phos-
phorylation of Parkin Ser65 by PINK1 is essential for both
activation of its E3 ligase activity and the robust generation of
phospho-ubiquitin in mature mammalian neurons.2.2. ParkinS65A/S65A knock-in mice exhibit selective
motor impairments
Since our ParkinS65A/S65A mice have been engineered with an
inactivating point mutation in the endogenous Park2 locus
and express comparable levels of Parkin protein, we specu-
lated that our model may bypass epistatic compensation
induced by the loss of total protein in traditional knockout
models. We therefore undertook a comprehensive behaviour-
al characterization of our ParkinS65A/S65A mice to investigate
if the loss of endogenous Parkin phosphorylation could influ-
ence striatal function in vivo. Overall, ParkinS65A/S65A mice
exhibited normal gross development and ageing in terms of
neurological and behavioural function. We employed the
raised balance beam as a more sensitive and powerful test
of voluntary locomotor function, balance and coordinated
limb use in our mice. Strikingly, we observed that Par-
kinS65A/S65A mice at 12 and 18 months of age exhibited
consistent impairments in all measures of balance beam per-
formance compared with wild-type control mice (figure 3a).
Both the latency to turn towards the goal box when placedon the beam end (AGE  GENO: F1,32¼ 11.41, p, 0.01),
and the subsequent latency to cross the beam (AGE 
GENO  SEX: F1,32 ¼ 12.82, p, 0.01) were slower for Par-
kinS65A/S65A mice compared with wild-type controls, with
mutant males being slower to traverse the beam than their
female counterparts (figure 3a). Furthermore, quantitation
of foot-slips while traversing the balance beam demonstrated
that the number of forelimb (GENO: F1,47 ¼ 29.08, p, 0.01)
or hindlimb (GENO: F1,47 ¼ 38.52,
p, 0.01) slips made by ParkinS65A/S65A mice was greater than
controls (figure 3a), but this phenotype was not exacerbated
at 18 months. In addition to deficits in motor function, the
impairments observed in ParkinS65A/S65A mice to complete
the task, particularly during the ‘beam turn’ aspect, could
also indicate an underlying, yet subtle defect in cognitive
planning (figure 3a). Rotarod testing at 12 and 18 months
of age did not reveal any substantial differences between
ParkinS65A/S65A and wild-type mice (AGE  GENO: p ¼
0.058) (electronic supplementary material, figure S4).
Additionally, Parkin mutant mice did not exhibit any impair-
ments in gait in comparison to wild-type mice in terms of
stride length and stride width (electronic supplementary
material, figure S4). Although the rotarod is routinely used
to assess locomotor function in rodents, its lack of sensitivity
and confounding variables are well recognized [27]. Overall,
these data demonstrate that endogenous Parkin inactivation
in vivo results in selective deficits in a sensitive test of volun-
tary motor function. Consistent with our results, deficits in
fine motor coordination were reported in one previous
characterization of Parkin knockout mice generated by tar-
geted deletion of exon 3 [17]; however, in another
independently generated exon 3 deleted knockout model,
no motor deficits were reported although these mice
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Figure 3. ParkinS65A/S65A mice exhibit selective impairments on a sensitive task of voluntary motor function. (a) Balance beam performance in ParkinS65A/S65A (KI)
and wild-type mice at 12 months and 18 months of age. Animals were assessed by their ability to reach a platform by competently traversing a raised and tapered
beam. The performance was recorded by the number of errors scored as slips (forelimb, hindlimb and combined). ParkinS65A/S65A mice made significantly more
forelimb errors and hindlimb errors at 12 and 18 months ( p, 0.01) than their WT littermates. The ParkinS65A/S65A mice also demonstrated an age-related decline
in their ability to orientate themselves on the beam end and cross the beam, resulting in longer latencies on both measures compared to WT littermates ( p,
0.01). Error bars represent the standard error of the mean. (b) Striatal RCR is affected in ParkinS65A/S65A mice. Mitochondrial respiratory acceptor control ratios in the
striatum, midbrain, and cortex of 1-year-old aged wild-type and ParkinS65A/S65A mice (n ¼ 10 per group).
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similar fine motor deficits were found in Pink1 knockout
mice in the absence of nigrostriatal degenerative pathology
[29], further underscoring the importance of performing
more sensitive behavioural testing in mouse models of PD.
In our study, we were unable to determine the age-of-onset
of the motor deficits, although it was reported that Pink1
knockout mice take approximately six months to exhibit
detectable locomotor dysfunction [29].
Given the mitochondrial-centric functions ascribed to
the PINK1–Parkin dyad, we next investigated if the selective
motorphenotype in ourParkinS65A/S65Amice could be attributed
tomitochondrial dysfunction.We assayedmitochondrial respir-
ation in discrete adult brain regions from 3-month old and
12-month-old wild-type andmutant mice using high-resolution
(Oroboros Oxygraph-2k) respirometry [20]. In 3-month-old
mice, we observed no difference in the respiratory control ratio
(RCR) defined as State3ADP/State4 that reflects mitochondrial
oxidative phosphorylation coupling efficiency independently
of mitochondrial content [30,31] (electronic supplementary
material, figure S5a). By contrast, we detected a highly selective
and consistent difference in mitochondrial RCR between the
striatum of 12-month-old ParkinS65A/S65A and wild-type mice
but not in other brain regions including cortex (figure 3b and
electronic supplementarymaterial, figure S5b). This is consistent
with previous reports of impaired mitochondrial respiration in
select brain regions of aged Parkin knockout mice [20], and
suggests that Parkin Ser65 phosphorylation contributes to
mitochondrial integrity in this brain region.2.3. Nigrostriatal integrity and basal mitophagy levels
are normal in ParkinS65A/S65A knock-in mice
The observed locomotor and striatal mitochondrial dys-
function in ParkinS65A/S65A mice suggested that endogenousParkin inactivation could also negatively impact nigrostriatal
integrity in vivo. We next performed histological analysis
of the substantia nigra of aged (approx. 18 months)
ParkinS65A/S65A and wild-type mice to investigate if the
impaired viability of nigrostriatal dopaminergic (DA) neur-
ons might account for the selective motor defects in
ParkinS65A/S65A mice. Inactivation of endogenous Parkin did
not influence striatal anatomy or volume in aged mice
(figure 4a–c). Nigrostriatal projections are highly complex,
with a single DA neuron capable of innervating up to 2%
of its terminal target field [5,32]. Although total DA neuron
numbers were comparable between ParkinS65A/S65A
mice and controls (data not shown), it is conceivable that
differences in target-field arborization could account for
the observed motor defect in our mutant animals. At a
gross neuroanatomical level, conventional chromogenic
tyrosine hydroxlase (TH)-immunohistochemistry revealed
indistinguishable striatal innervation between genotypes
(figure 4a); however, this approach does not permit a
high-resolution analysis of the nigrostriatal projection. To
determine whether Parkin inactivation could impact the onto-
geny and arborization of DA neurons in vivo, we employed
whole volume imaging of the entire nigrostriatal pathway
within intact, optically cleared adult brains using iDISCOþ
[22,33,34]. This approach enabled utilization of confocal
microscopy to assess the degree of innervation and overall
connectivity between aged ParkinS65A/S65A mice and litter-
mate control mice at high resolution. Using this approach,
we successfully resolved DA projections in wild-type and
ParkinS65A/S65A mice; however, we observed no differences
between groups (figure 4b). Dysfunction in non-neuronal
cells is also a reported feature of PD mouse models [35]. How-
ever, immunohistochemical labelling of microglia and
astroglia by Iba1 and GFAP, respectively, revealed no overt
differences between wild-type and ParkinS65A/S65A mice (data
not shown). To further investigate nigrostriatal function, we
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Figure 4. ParkinS65A/S65A mice do not exhibit nigrostriatal degeneration or defective mitophagy. (a–c) Striatal innervation is indistinguishable between wild-type
and ParkinS65A/S65A (KI) mice. (a) No differences in neuron number or striatal innervation were observed by anti-tyrosine hydroxylase (TH)-based immunohistochem-
istry analysis of midbrain and striatum between genotypes. (b) Striatal innervation analysis of TH-positive DA neurons within intact brains processed by iDISCOþ.
Arborization of DA neurons is indistinguishable between wild-type and KI mice. (c) No differences were observed in striatal volume between genotypes. Error bars
represent standard errors of the mean. Striatal dopamine levels are unaltered in ParkinS65A/S65A mice. HPLC analysis revealed no differences in dopamine (DA) and
3,4-dihydroxyphenylacetic acid (3,4-DOPAC) levels between wild-type and KI mice (n ¼ 10 per genotype). Data represent mean values+s.e.m. n.s., not significant.
(d ) Basal mitophagy is unaltered by endogenous Parkin activation in vivo. Maximum z-projections of midbrain DA neurons from mito-QC wild-type and KI mice
immunolabelled with antibodies to TH (blue) and LAMP1 (greyscale). Arrows point to mitochondria and arrowheads point to mitochondria associated with (autop-
hago)lysosomes/mitolysosomes as defined by co-localization of LAMP1 and mito-QC staining. Mitochondrial delivery to lysosomes (mitophagy) is associated with
quenching of GFP signal of the mito-QC reporter and residual mCherry only signal intensity. Scale bar 5 mm. Asterisks indicates cells within insets. (e) Quantitation
revealed no differences between mitophagy in DA cell bodies or axons. Results are expressed as mean values+ s.e.m.
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mice. We rapidly dissected striatal tissue from age-matched
wild-type and ParkinS65A/S65A littermates and subjected these
to HPLC analysis. We observed comparable levels of DA andDA turnover in wild-type and ParkinS65A/S65A striata (figure 4c),
indicating that in ourmouse model, genetic ablation of endogen-
ous Parkin phosphorylation and activation is not sufficient to
impact DA neurotransmission in vivo. Collectively, these data
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a selective locomotor defect in the absence of structural nigrostria-
tal dysfunction in vivo. Importantly, our findings highlight the
importance of Parkin activation under steady-state conditions
in vivo.
Parkin has received most attention for its role in modulat-
ing mitochondrial quality control [5]. Maximal activation of
Parkin E3 ligase activity leads to ubiquitylation of myriad sub-
strates on the mitochondrial outer membrane, that engage
autophagy receptors and drive the elimination of damaged
mitochondria via mitophagy [4–6]. This widely accepted and
reproducible model is largely based on in vitro findings, how-
ever recent advances in mouse genetics using the mito-QC
andmt-Keima reporter models have revealed the physiological
nature of basal mitophagy in vivo [22,36,37]. Furthermore, DA
neurons have recently been shown to undergo high levels of
mitophagy in vivo which occurs independently of PINK1
[38,39]. To investigate the regulation of basal mitophagy in
the context of endogenous Parkin inactivation in mammals,
we crossed ParkinS65A/S65A mice with the mito-QC mitophagy
reporter model to generate ParkinS65A/S65A-mito-QC mice. An
assessment of wild-type and S65A mito-QC animals revealed
that basalmitophagy in nigrostriatal DA cell bodies and projec-
tions was indistinguishable between wild-type and mutant
mice (figure 4d,e). These data reveal that nigrostriatal mito-
phagy is unaffected in a mouse model of endogenous Parkin
inactivation exhibiting selective defects in motor and
mitochondrial function.
2.4. PARK2S65N mutations cause human Parkinson’s
disease via direct disruption of the PINK1–Parkin
axis
Human patients with PARK2 mutations typically present
with early onset PD displaying slow progression and sus-
tained response to L-DOPA. Mutations in several key
regulatory residues of Parkin have previously been identified,
including Cys431Phe which disrupts the catalytic acceptor
cysteine within the RING2 domain [40]. However, to date,
no mutations affecting the Ser65 phosphorylation site have
been reported. Here we report the first clinical and genetic
evidence of PD associated with homozygous mutations at
p.S65N, the critical node of the PINK1–Parkin pathway.
2.5. Case series
2.5.1. Case 1
We report a 71-year-old Finnish male, diagnosed with early
onset PD at the age of 40 years with no reported family history
of Parkinson’s. His symptomatic presentation included rigidity
of the lower limbs that was initially more marked on the
left-hand side, and he exhibited shortness of steps.He has conti-
nued to experience rigidity throughout his disease course,
without the development of tremor. Recently, the patient has
suffered from a mild gait disturbance with occasional freezing
and postural instability. Overall, the progression of his illness
has been exceptionally slowwith a sustained response to medi-
cation that currently comprises: levodopa (300–400 mg d21),
pramipexole (2.1 mg d21) and selegiline (10 mg d21). On exam-
ination during the years 2016–2017, hewas categorized at stage
2.5 of the modified Hoehn and Yahr Scale, with a UnitedParkinson’s Disease Rating Scale (UPDRS) score of 41/199
(electronic supplementary material, table S1) Dopamine trans-
porter (DaT) single-photon emission computerized
tomography (SPECT) of the brain demonstrated reduced den-
sity of DA synaptic terminals in the caudate and putamen
consistent with degenerative PD (figure 5a).
Targetednext-generation sequencing (NGS) revealed that the
patient carried a novel homozygous c.194G. Avariant in exon
3 of the PARK2 gene causing an amino acid change p.Ser65Asn
(S65N) in the PARKIN protein (figure 5b). The variant is very
rare: only two heterozygous carriers among 122 271 subjects
were found in the Genome Aggregation Database (gnomAD)
with an allelic frequency of 8.2  1026. In the Exome Aggrega-
tion Consortium (ExAC) database, two heterozygotes were
found among 60 691 subjects (allele frequency 1.6 1025). Fur-
thermore, the variant site is highly conserved in vertebrates
(electronic supplementary material, figure S6a), and in silico
analysis of the variant by the method of Combined Annotation
Dependent Depletion (CADD) [42] predicted that the mutation
is deleterious with a CADD C-score of 25.5. We analysed
coding variants in 82 selected PD-associated loci (electronic sup-
plementary material, table S2) with a CADD C-score of greater
than 20 and population carrier frequency less than 1%, but did
not find any other likely pathogenic variant in S65N-M70.
2.5.2. Case 2
A 60 year-old Caucasian female diagnosed with PD at the age
of 54 was identified from the Parkinson’s Progression Mar-
kers Initiative (PPMI). Her initial clinical features were
bradykinesia and gait difficulty on the right side. She exhib-
ited characteristic but mild motor symptoms for PD and no
atypical features have been observed. Twelve months follow-
ing her diagnosis, she was commenced on pramipexole
resulting in a positive and sustained response (current
dosing 2.25 mg of pramipexole/day). At her latest examin-
ation, the patient was categorized at Stage 2 of the Hoehn
and Yahr Scale, and she has also been examined using the
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) for
5 years (scores from latest examination are provided in
electronic supplementary material, table S1).
The patient has also been followed up by DaT imaging for
four years, which has demonstrated reduced density of DA
synaptic terminals in the caudate and putamen consistent
with DA denervation (striatal binding ratio (SBR) calcula-
tions from the latest session are provided in electronic
supplementary material, table S1).
Genetic analysis of the individual revealed a homozygous
Parkin p.S65N mutation. Analysis of 82 PD-associated loci
revealed three other gene variants (in POLG, MC1R and
Glucocerebrosidase (GBA) (electronic supplementary material,
table S3) that passed our filtering criteria (CADD C-score
greater than 20, carrier frequency less than 1%). A heterozygous
recessive variant (p.G268A) inPOLG has been linked to autoso-
mal recessive/sporadic progressive external ophthalmoplegia
(PEO) in compound heterozygous or homozygous form
[43,44], but also described as single-heterozygous in a child
with a syndrome including Parkinsonism born fromconsangui-
neous parents (probable autosomal recessive mode of
inheritance) [45]. She also carried another POLG variant, a
rare inframe deletion (exon2:c.153_158del:p.Gln54_Gln55del)
in a tandem repeat region of POLG; however, this is likely a
benign variant, given a CADD C-score of 6.2. Overall, we did
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ease-causing in the patient. A rare heterozygous variant
(p.R142H) was detected in the MC1R gene. This gene was
initially found to be associatedwith PD, but subsequent studies
with large patient cohorts have not supported this finding [46–
49]. Furthermore, the p.R142H variant has to date only been
associated with red hair and not PD [46]. Thus, we did not con-
sider p.R142Hbeing a disease-causing variant in this patient. By
contrast, a heterozygous p.N409S variant in GBAwas detected,
which is a recognized susceptibility factor for PD [50] althoughthe variant does not always lead to PD [51]. Therefore, we
conclude that the PARKIN p.S65N mutation is likely to be the
major disease-causing variant in the patient, although we
cannot exclude that the GBA p.N409S variant may contribute
to pre-disposition and/or the clinical phenotype of the patient.
2.5.3. Functional analysis of the PARKINS65N/S65N mutation
We initially assessed the pathogenicity of the ParkinS65N/S65N
mutation by assaying PINK1–Parkin signalling in Flp-In
Figure 5. (Opposite.) Discovery and characterization of case 1: a human PD-causing Parkin mutation at Ser65. (a) Dopamine transporter imaging (DaT scan) results
with region-based semi-quantitative analysis. 123I-FP-CIT brain single-photon emission computed tomography (SPECT) or DaT scan imaging measures DAT density in
presynaptic terminals of the DA neurons projecting from the substantia nigra to dorsal striatum (caudate nucleus and putamen) thereby enabling assessment of the
structural integrity of the nigrostriatal pathway in humans. DaT SPECT imaging was performed three hours after an intravenous injection of 186 MBq 123I-FP-CIT
using a double head gamma camera with a fan beam collimator. Thyroidal uptake was blocked by 300 mg of oral potassium perchlorate before the tracer injection.
Occipital lobe was used as a reference region of non-specific binding. The Z-scores in the top right of the figure indicate significant deviation from the population
mean values for both the left and right caudate and putamen. In the putamen, the DAT density was slightly more reduced, which is typical of the rostro-caudal
pattern of uptake loss in PD. (b) Electropherogram detailing S65N mutation data (Exon 3 G . A). (c) Parkin S65A and S65N mutants display reduced Parkin
activation in response to PINK1 activation. Flp-In T-Rex-HeLa cells stably expressing wild-type (WT), S65A and S65N Parkin were induced with 0.1 mg ml– 1 dox-
ycycline for 24 h prior to stimulation with DMSO or 10 mM CCCP at indicated timepoints (1 h or 3 h). Whole-cell lysates were subjected to immunoblot analysis
using the indicated antibodies. For detection of ubiquitylation (marked by open circles), lysates were subjected to ubiquitylated-protein capture by His-Halo-Ubi-
quilin1 UBA-domain tetramer (HALO-UBAUBQLN1), prior to immunoblot with anti-CISD1 (Proteintech Europe) and anti-Miro1/2 (DSTT, S531D, 5th bleed). (d ) Activity-
based profiling of Parkinson’s disease associated Parkin S65N patient-derived fibroblasts. Primary fibroblasts derived from skin biopsies from a healthy subject (WT)
and a PD patient harbouring a Parkin S65N homozygous mutation were profiled with E2-ubiquitin-based probe to monitor Parkin E3 transthiolation activity as
described previously [41]. Mitochondrial depolarization does not activate the PINK1–Parkin pathway in Parkin S65N patient cells (CCCP treatment (3 h,
10 mM)). (e) Composite schematic illustrating the X-ray crystal structure of the Parkin S65N disease mutant, superimposed over the wild-type structure (PDB
ID: 5C1Z, Grey). ParkinS65N structure is depicted in colour: UBL (teal), RING0 (magenta), RING1 (orange), IBR (blue), REP (yellow) and RING2/Rcat (red).
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wild-type Parkin, a non-phosphorylatable S65A mutant and
the S65N mutant of Parkin. Following the induction of
Parkin expression, cells were treated with 10 mM CCCP or
DMSO for 1 or 3 h. Immunoblotting of protein extracts
demonstrated that the S65N mutation was functionally
equivalent to the S65A mutation, leading to both a loss of
both Parkin activation (as judged by reduced CISD1 and
Miro1/2 substrate ubiquitylation) and reduced phospho-
ubiquitin accumulation (figure 5c). We next interrogated the
influence of the S65N mutation on endogenous Parkin func-
tion, by assaying its activity and downstream signalling in
patient-derived cells upon mitochondrial depolarization. Pri-
mary fibroblast cultures were established from a skin biopsy
of the Finnish patient with homozygous Parkin S65N
mutation, and an unaffected human control. Cultures were
treated with 10 mM CCCP or DMSO for 3 h to induce
PINK1 stabilization and activation (electronic supple-
mentary material, figure S6b). Immunoblotting with
anti-phospho-Ser65 Parkin antibodies demonstrated that
Parkin phosphorylation was abolished in cells expressing
S65N (electronic supplementary material, figure S6b). This
was associated with substantial reduction of Parkin E3
ligase activity as judged directly by ubiquitylation of CISD1
in PARKINS65N/S65N fibroblasts (electronic supplementary
material, figure S6b). Furthermore, we observed reduced
accumulation of phospho-ubiquitin in patient fibroblasts
compared with control cells, indicating reduced Parkin E3
ligase activity (electronic supplementary material,
figure S6b). We further confirmed loss of Parkin E3 activity
in patient-derived primary cultures by deploying a
chemical probe that measures transthiolation activity of
Parkin via covalent labelling of its active site cysteine
residue Cys431 [41]. The probe revealed robust labell-
ing of activated wild-type human Parkin in control
fibroblasts, whereas this was completely disrupted in
PARKINS65N/S65N mutant fibroblasts (figure 5d ). Interest-
ingly upon mitochondrial depolarization, we observed a
partial reduction in mitochondrial PINK1 stabilization in
the PARKINS65N/S65N mutant fibroblasts (electronic sup-
plementary material, figure S7) and this is consistent
with similar findings observed in CRISPR/Cas9 mediated
S65A mutant human ES cell-derived neurons stimulated
with A/O [25].We next investigated the effect of the endogenous PAR-
KINS65N/S65N mutation on basal and depolarization-induced
mitophagy. We first generated a stable mitophagy reporter cell
line via retroviral transduction ofmito-QC [39,52] in both control
and PARKINS65N/S65N patient fibroblast lines. To induce sub-
stantial levels of mitophagy in culture, patient and control cells
expressing mito-QC were stimulated with A/O for 24 h. Upon
A/O stimulation, we observed no difference in mitophagy
between control and PARKINS65N/S65N mito-QC cells (electronic
supplementary material, figure S8). These data are consistent
with a previous report demonstrating that endogenous Parkin
is dispensable for basal and depolarization-induced mitophagy
in patient-derived primary fibroblasts [52].2.5.4. Structural analysis of the ParkinS65N mutant protein
To understand precisely how the pathogenic S65N mutation
affects Parkin activity, we crystallized and solved the struc-
ture of the novel human Parkin PD mutant (UBLR0RBR,
D84–143) at 2.9 A˚. Comparative analyses of wild-type and
ParkinS65N x-ray crystal structures did not reveal any confor-
mational differences between the wild-type and mutant
protein (figure 5e and electronic supplementary material,
figure S6c), indicating that the S65N mutation does not sig-
nificantly perturb Parkin structure. However, as the S65N
mutation prevents incorporation of a phosphate group at
this position, the absence of a negative charge at the UBL-
IBR interface inhibits the ability of ParkinS65N to adopt the
open conformation required for full E3 activity. This contrasts
to wild-type Parkin, where phosphorylation at Ser65 induces
key conformational changes and new interactions [53–56].3. Discussion
Combining a novel mouse knock-in model and unique
human clinical case studies, we present the most compelling
evidence to date demonstrating the physiological and clinical
significance of PINK1-dependent Parkin Ser65 phosphoryl-
ation. Furthermore, despite over 20 putative substrates
reported in the literature [57,58], our research indicates that
inactivation of this PINK1 phosphorylation site on Parkin
alone is sufficient for humans to develop early onset
Parkinson’s disease (PD).
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in mammalian models of PINK1 and Parkin has proved chal-
lenging, because it has been difficult to recapitulate a PD-like
neurodegenerative phenotype in rodents, with the notable
exceptions of mutant Parkin over-expression in mice and
rats [59,60]; the Pink1-null rat model [61]; and exposure of
Parkin-null mice to chronic mitotoxic stress [21]. While Par-
kinS65A/S65A mice have an anatomically intact nigrostriatal
pathway with no detectable loss of viability, denervation or
dopamine depletion even after ageing for 18 months
(figure 4a–c), we observed selective locomotor dysfunction
particularly on balance beam performance (figure 3a). Our
results are consistent with previous reports of motor deficits
reported in Parkin knockout mice [17] and Pink1 knockout
mice [29] in the absence of nigrostriatal pathology.
The neurobiological basis of the fine motor defects emer-
ging in Parkin and Pink1 genetic models is poorly understood.
We did not observe any substantial changes in the absolute
levels of dopamine in Parkin knock-in mice. Interestingly,
multiple lines of evidence suggest that Parkin knockout
mice exhibit compartment defects with reduced striatal
synaptic release of dopamine, associated with reduced
expression of both the dopamine transporter (DAT) and ves-
icular monoamine transporter (VMAT2) and higher levels of
extracellular dopamine in the striatum [17,18]. Mild mito-
chondrial defects have also been reported in 24-month old
Parkin knockout mice that are not observed in younger
mice (9 months of age) [20]. These effects were restricted to
the striatum, and not detected in other brain regions includ-
ing the midbrain or cortex [20]. Using a similar approach,
our analysis revealed a mild, age-dependent defect in mito-
chondrial respiration in the striatum of Parkin knock-in
mice (figure 3b). Interestingly, this was not associated with
any change in basal nigrostriatal mitophagy in Parkin
knock-in mice (figure 4d,e). Our current findings are also con-
sistent with our recent demonstration of PINK1-independent
mitophagy in vivo [39]. Recent analysis of Drosophila melano-
gaster models expressing fluorescent mitophagy reporters
has also revealed that basal mitophagy proceeds indepen-
dently of both PINK1 and Parkin in vivo [38]. Nevertheless,
because cell culture studies in vitro provide a compelling
case for Parkin activation in stress-evoked mitochondrial
quality control pathways [4–6], it will be vital to investigate
if nigrostriatal mitophagy is specifically affected in models
of constitutive mitotoxicity reporting PD-relevant pathology,
e.g. Polg mutator mouse crossed with Parkin knockout mice
[21,62]. Ultimately, our findings highlight the importance of
uncovering the mitophagy-independent pathways by which
endogenous Parkin sustains striatal function and mitostasis
during ageing. Our data also adds to the growing body of
evidence that suggests multiple mitophagy pathways operate
to sustain mitochondrial quality control during specific con-
texts i.e. under basal conditions compared to extreme or
chronic stress.
At the molecular level, the feed-forward mechanism
of Parkin activation stipulates that (i) PINK1-dependent
generation of phospho-ubiquitin stimulates Parkin recruitment
to damaged mitochondria, (ii) this primes Parkin for phos-
phorylation by PINK1 and thus maximal activation, (iii)
leading to further phospho-ubiquitin accumulation [4–6].
Evidence for this model includes the demonstration that the
Parkin His302Ala (H302A) mutant, that cannot bind phos-
pho-ubiquitin but is catalytically competent, exhibits reducedmitochondrial recruitment, Parkin Ser65 phosphorylation
andubiquitylation of substrates inHeLacells [11,41]. However,
HeLa studies also suggest that the initial amount of phospho-
ubiquitin generated by PINK1 (independent of Parkin activity)
is likely to be low because over-expression of the catalytically
inactive Parkin Cys431Ser mutant does not result in signifi-
cantly detectable phospho-ubiquitin accumulation [12,15].
Consistent with this latter observation, we did not observe
any phospho-ubiquitin accumulation in mature primary corti-
cal neurons (figure 2) or adult primary lung fibroblasts
(electronic supplementary material, figure S3) subjected to
mitochondrial depolarization from ParkinS65A/S65A and Parkin
knockout mice. This is consistent with recent analysis of
CRISPR/Cas9-mediated S65A mutant human ES cell-derived
neurons stimulated with A/O [25]. By contrast, we did detect
phospho-ubiquitin accumulation in ParkinS65N mutant patient-
derived fibroblasts and HeLa cells (figure 5c and electronic
supplementary material, figure S6b), albeit at lower levels than
wild-type cells, suggesting potential redundancy of Parkin in
these cell types with both Parkin-dependent and Parkin-
independent formation of phospho-ubiquitin. The MUL1 E3
ligase has recently been reported to operate in a parallel pathway
to Parkin in non-neuronal cells, and could account for the
phospho-ubiquitin we observe in our human cell systems
[63], although further work is required to substantiate this.
We and others have previously demonstrated that
phospho-ubiquitin can partially activate recombinant
non-phosphorylatable Parkin S65A protein in vitro [8,12].
Despite detectable accumulation of phospho-ubiquitin in
fibroblasts, we observed complete loss of E3 activity in PAR-
KINS65N/S65N mutant cells. The interaction affinity between
the non-phosphorylated Parkin-phospho-ubiquitin complex
with its charged E2 Ub is approximately 20-fold lower
than that for the Phospho-Ser65-Parkin and phospho-ubiquitin
complex [64], which may partly explain the lack of activation of
endogenous ParkinS65N (and similarly ParkinS65A) protein.
Our results therefore highlight the importance of studying
signalling pathways at endogenous levels in physiologically
relevant systems. Moreover, our data may also be explained
by recent structural analysis of Parkin activation mechanisms.
Initial binding of phospho-ubiquitin triggers a conformational
shift that exposes a donor ubiquitin-binding site and partial
activation of Parkin catalytic activity [54]. The subsequent
PINK1-dependent phosphorylation of Parkin Ser65 ultimately
drives Parkin activation by a series of structural alterations. In
particular, displacement of the phospho-Ubl domainmaintains
interaction of the ubiquitin-charged E2 to the RING1 domain,
and the phospho-Ubl subsequently binds to a basic phos-
phate-binding site on RING0 (flanked by residues Lys161 and
Lys211 as well as Arg163) [53,55,56]. The binding of phospho-
Ubl to RING0 leads to the release of the catalytic RING2
domain therebyexposingC431 topromote full Parkin activation
and enhancing interactions with E2 [53,55,56]. Collectively,
our endogenous neuronal results combined with recent struc-
tural insights highlight the pre-eminent status of Parkin Ser65
phosphorylation in modulating its catalytic activation.
The clinical importance of endogenous PINK1-mediated
Parkin phosphorylation is substantiated by our discovery of
two unrelated PD patients harbouring novel mutations at
Parkin Ser65. Numerically, mutations in Parkin are associated
with early onset PD, accounting for approximately 40% of
cases with age of onset below 45 years; however, patients
with pathogenic Parkin inactivating mutations have been
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the second case [65]. In line with our mouse data, we found
that basal and depolarization-induced mitophagy in S65N
patient-derived primary fibroblasts was not diminished,
despite a loss of Parkin E3 ligase activity (electronic sup-
plementary material, figure S8). In the future, it will be
exciting to address whether this is the case in a more neural
context, by generating dopamine neurons derived from
human pluripotent stem cells (hPSCs).
Although PINK1–Parkin signalling constitutes a clear
pathway that modulates depolarization-induced mitophagy
in vitro, basal mitophagy is unaffected in both Pink1 knockout
and Parkin S65A knock-in mice. Though the clinical signifi-
cance of PINK1–Parkin signalling is incontrovertible, the
contribution of this pathway to mitophagy in vivo remains
unclear, as does the contribution of dysregulated mitophagy
to PD [66]. We predict that distinct mitophagy pathways
orchestrate mitochondrial homeostasis under steady-state
and stress-response scenarios.
In summary, this study is the first to establish both the
physiological and clinical significance of PINK1-mediated
phosphorylation of Parkin at serine 65. Our findings shed
much-needed light on endogenous Parkin function and
should provoke a reassessment of how it orchestrates
cell-specific mitostasis in vivo.4. Material and methods
4.1. Generation and validation of ParkinS65A/S65A knock-
in mice
ParkinS65A/S65A mice were generated by TaconicArtemis
GmbH, using a targeting strategy to introduce a constitutive
knock-in of a point mutation (KI-PM) in the Park2 gene by
homologous recombination in mouse ES cells. The targeting
strategy was based on NCBI transcript NM_016694.3. Exon 1
contains the translation initiation codon, and the S65A
mutation was introduced into exon 3. A positive selection
marker (puromycin resistance, PuroR) flanked by FRT sites
was inserted into intron 2. The targeting vector was generated
using BAC clones from the C57BL/6 J RPCIB-731 BAC library
and transfected into the TaconicArtemis C57BL/6N Tac ES cell
line. Homologous recombinant clones were isolated using
positive and negative (thymidine kinase, TK) selection, and
the constitutive KI-PM allele was obtained after Flp-mediated
removal of the selection marker. This KI-PM allele was pre-
dicted to express the mutated Park2 S65A protein product.
The remaining recombination site will be located in a non-
conserved region of the genome. The knock-in mice were
generated and maintained on an inbred C57BL/6J back-
ground. Genotyping was performed by endpoint PCR using
genomic DNA isolated from tails using the following
primer sets at an annealing temperature of 608C: Primer 1
(50GAACAAGATAGGAGCACAGAAGG 30) and Primer 2
(50GACCAATTTACCTCTCGAGTGC 30) that enabled detec-
tion of the wild-type (290 bp) and S65A knock-in (365 bp)
alleles. The mito-QC mouse model used in this study was
generated as previously described on a C57BL/6N back-
ground strain [22] and crossed with Parkin S65A knock-in
heterozygote animals to produce homozygous knock-in
animals and wild-type littermate controls with endogenous
mito-QC reporter.4.2. Materials and reagents
HaloLink resin was purchased from Promega. All mutagen-
esis was carried out using the QuikChange site-directed
mutagenesis method (Stratagene) with KOD polymerase
(Novagen). All DNA constructs were verified by the MRC
Protein Phosphorylation and Ubiquitylation Unit (PPU)
DNA Sequencing Service, School of Life Sciences, University
of Dundee, using DYEnamic ET terminator chemistry (Amer-
sham Biosciences) on Applied Biosystems automated DNA
sequencers. DNA for bacterial protein expression was trans-
formed into Escherichia coli BL21 DE3 RIL (codon plus) cells
(Stratagene). Stock solutions of carbonyl cyanide m-chloro-
phenyl hydrazone (CCCP; Sigma), antimycin A (Sigma)
and oligomycin (Sigma) were used for experiments in cells.
Unless otherwise specified, general reagents and chemicals
were from Sigma-Aldrich (Merck) and cell culture reagents
were from Gibco/Invitrogen (Thermo Fisher Scientific). All
cDNA plasmids, antibodies and recombinant proteins gener-
ated in house for this study are available on request through
our dedicated reagents website: https://mrcppureagents.
dundee.ac.uk/
4.3. Mouse motor and behavioural studies
In total, 51 PARK2 S65A mice were used for behavioural
experiments in groups which consisted of 25 wild-type (14
males and 11 females) and 26 Park2S65A/S65A mice (11 males
and 15 females). At 18 months 35 mice remained, 16 wild-
type (10 males and 6 females) and 19 Park2S65A/S65A mice
(9 males and 10 females). Mice were housed in sex-matched
littermate groups of between two and five animals per cage
with lights adjusted to a 12 L : 12 D cycle (lights on at 06.30)
and with a constant ambient room temperature of 218+
18C. Animals had ad libitum access to food and water
throughout. The mice underwent behavioural testing at
12 months and 18 months of age and all experiments were
conducted in accordance with the 2013 European Union
Directive 2010/63/EU and the UK Animals (Scientific Pro-
cedures) Act of 1986 and local ethical review at the
University of Cardiff.
The motor test battery has been described previously else-
where [67], but briefly mice were tested for simple
neurological deficits using: clasping and reaching assays;
accelerating rotarod and balance beam test to measure
motor coordination and balance; 30 min and 24 h open field
activity; footprint analysis to measure changes in gait; and
inverted grid task to measure grip strength. For the rotarod
test (Ugo Basile, Varese, Italy), mice are placed on a rotating
beam which accelerates. Initial training consisted of training
the mice at different speeds for 2 min (4, 8 and 12 r.p.m.).
Data were collected from five sessions at the 12-month time
point and two sessions at the 18-month time point whereby
the mice were placed on the rod that accelerated from 4 to
40 r.p.m. over 5 min. The latency of the mice to fall from
the beam was recorded and used as a measure of motor
coordination. For the balance beam test (see above reference
for dimensions), each mouse was trained to run the beam
prior to the test session. This consisted of starting the mice
in the goal box at the top of the inclined beam and over
repeated exposures moving the starting point on the beam
to the lower end (start point) such that the mice ran further
as the training progressed. Training was complete when the
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from the beam) and the mouse turned and ran the length of
the beam unprompted. Foot-slips were recorded when a foot
slipped from the beam onto the narrow ledge that ran either
side of the length of the beam. Each mouse provided data
(fore and hind limb foot-slips, latency to turn and cross the
beam) from two runs for analysis. Gait analysis was run
using a footprint test whereby the feet of the mice were
painted with red (front feet) and blue (rear feet) non-toxic
water-based paint, and the mice were permitted to run a
1-m corridor that was fitted with paper on the floor such
that they left coloured paw prints. The paw print patterns
permit the measurement of variation in gait: stride length;
base width (distance between left and right front/hind
limbs); front/hind paw overlap (in normal locomotion the
hind paw placement overlaps closely with the location
where the fore paw had previously landed; gait impairment
is manifest by an increase in the magnitude and variability
of the separation. For the motor activity testing using an auto-
mated system (Med Associates Inc, Vermont, USA), mice
were placed in an open field arena for 32 h with free access
to food and water throughout. Data were collected automati-
cally with activity being measured as the number of infrared
beam breaks. Activity was measured as the initial 30 min
period (transfer activity) and a 24 h period (15.00 to 15.00)
to capture a circadian cycle. In addition, several simple
behavioural assessments were run: clasping and reaching
reflexes where the mice is suspended by the tail and low-
ered to the benchtop with clasping and reaching
measured through observation and recorded as present
or absent; negative geotaxis, measuring the natural incli-
nation of the mouse to face upwards when placed head
down on a vertical grid, with the mouse being allowed
30 s to correct its orientation to the upright position; and
horizontal grid grip strength, whereby the mouse is
placed on a flat grid surface which is then rotated 1808
along the horizontal axis such that the mouse is clinging
to the underside of the grid, the maximum time for the
mouse to remain upturned being 60 s without falling.
4.3.1. Statistical analyses of mice behavioural studies
Parametric split-plot analyses of variance using age as the
within groups factor and genotype and sex as between-
group factors were used where applicable as three-way
ANOVAs. All statistical analyses were conducted on
GENSTAT 17 (VSN International, Hemel Hempstead, UK).
Missing values were corrected with an inbuilt linear interp-
olation routine. For non-parametric data, x2 was used to
determine significance. Significance level was taken at
95% confidence.
4.4. Immunohistochemistry, iDISCOþ and microscopy
Transcardial perfusion was performed under terminal gen-
eral anaesthesia to obtain tissues for histological analyses.
Histology, immunohistochemistry, immunocytochemistry
and confocal microscopy were performed as previously
described [22,39,68,69], with minor modifications. Following
terminal anaesthesia via intraperitoneal administration of
Euthatal, adult animals were trans-cardially perfused with
phosphate-buffered saline (PBS) to remove excess blood. Tis-
sues were rapidly harvested and processed by immersionfixation in freshly prepared 3.7% PFA at pH 7.0 in 0.2 M
HEPES. For mito-QC animals, transverse brain sections
(200 mm) were acquired using a vibratome (Leica). For chro-
mogenic immunohistochemistry and stereological analyses,
coronal brain sections (40 mm) were cut on a sledge micro-
tome equipped with a freezing stage (Leitz) and processed
for free-floating immunohistochemistry. The following pri-
mary antibodies were used: rat monoclonal anti-lysosomal
associated membrane protein 1 (LAMP1) (1D4B) (Cat#: sc-
19992 RRID: AB_2134495; Santa Cruz Biotechnology, Inc.);
rabbit, sheep and mouse anti-Tyrosine Hydroxylase (rabbit:
Cat#: AB152; RRID: AB_390204; sheep: Cat#: AB1542;
RRID: AB_90755; mouse: Cat#: MAB318; RRID:
AB_2201528; Millipore); rabbit polyclonal anti-Ionized cal-
cium binding adaptor molecule 1 (Iba1) (Cat#: 019-19741;
RRID: AB_839504 - Wako), chicken anti-GFP (Cat# GFP-
1020, RRID:AB_10000240; Aves Labs; Cat# ab13970,
RRID:AB_300798; Abcam). Alexa-Fluor conjugated second-
ary antibodies were obtained from Life Technologies
(Molecular Probes/Thermo Fisher Scientific) as described
previously [39]. VECTASHIELD Antifade Mounting
Medium H-1000 was used to mount tissue sections on
slides (Leica Surgipath). For cell counts and tinctorial histo-
chemistry, Cresyl fast violet (Nissl) stain was obtained from
Sigma-Aldrich (C5042-10G). For whole-mount imaging of
the nigrostriatal pathway in intact mouse brains, specimens
were processed, stained using rabbit-TH (AB152) and
optically cleared using the detailed protocol specified for
iDISCOþ [33] (https://idisco.info). Following the acquisition
of images from intact whole brains (dorsal and ventral sur-
faces), cleared brain specimens were hemisected along the
midline and subsequently bisected to facilitate deeper ima-
ging in the sagittal and coronal planes, respectively. Images
were acquired using a Zeiss LSM 710 laser scanning micro-
scope (Plan-Neofuar 340 objective, NA 1.30; Plan
Apochromat 363 objective NA 1.4; Plan Apochromat 320
objective, NA 0.8), or a Zeiss LSM880 Airyscan confocal scan-
ning microscope (ZEISS; Plan Apochromat 363 objective, NA
1.4) and processed using ZEISS ZEN software/Adobe PHOTO-
SHOP or IMARIS (Bitplane) for 3D isosurface rendering. Images
were digitally altered within linear parameters, with minimal
adjustments to levels and linear contrast applied to all
images.
4.5. Quantification and statistical analysis
Semi-automated quantitation images were processed with
VOLOCITY 6.3 image analysis software (PerkinElmer) using
algorithms developed to analyse object overlap and count
individual structures. For all analyses, we obtained images
using uniform random sampling by an experimenter blind
to all conditions. All images in each experimental group
were processed as a batch using identical protocols. All
images were prefiltered to suppress noise (3  3 median
filter). The same strategy was used to quantify all non-immu-
nolabelled mito-QC-labelled images using auto-thresholding
to identify objects (mean intensity þ 3 standard deviations).
Objects were filtered using a minimum size cutoff
(0.16 mm2) and touching objects were separated using a
guide size (0.4 mm2). Mitolysosomes were typically identified
on the basis of thresholded red signal not overlapping with
green (this condition was relaxed in the case of samples
where dequenching of the mito-QC probe was observed).
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instances, we employed LAMP1 immunohistochemistry to
verify the lysosomal nature of mitolysosomes and green chan-
nel/combined with LAMP1 immunostaining was used as a
proxy for mitolysosomes. In the case of immunolabels used
to identify cells of interest in brain sections (TH, Iba1), we
employed an autothresholding criterion of mean intensity þ
1.5 standard deviations. A minimum size of 0.16 mm2 was
required, and a ‘Fill Holes in Objects’ processing step was
applied.
Cell counts were conducted using two-dimensional
stereology with an automated stage and stereology module
‘NEWCAST TM’ from VISIOPHARM integrator system software
(Visiopharm) on an Olympus Bx50 microscope (Olympus
Optical Co. Ltd, Tokyo, Japan). For NeuN immunohisto-
chemistry, cell counts were conducted on a 1 : 12 series
throughout the entire striatum (left and right sides), with
the counting objective set at 100 and the randomized
sampling counting frame area at 285 mm2 and corrected
using the Abercrombie formula [70]. For the TH and Calbin-
din double labelling, cell counts were carried out on a 1 : 12
series through the substantia nigra with the counting objec-
tive set at 40, and all visible cells were counted within
this area with double-stained cells denoting A10 dopamine
cells and cells only stained for TH denoted as A9 dopamine
cells.
4.6. Mitochondrial respiration assays
Wild-type and Parkin S65A knock-in mice (10 per genotype)
were killed by decapitation without prior anaesthesia. A frag-
ment of the tail was retrieved for confirmation of the
genotype, determined by PCR amplification, as previously
described [71]. The brains were rapidly removed and the
regions of interest (striatum, midbrain and cortex) dissected
on ice and weighed. Post-nuclear supernatants were obtained
by manual homogenization of brain samples in nine volumes
of isolation buffer (300 mM sucrose, 1 mM EGTA, 5 mM
Tris–HCl pH 7.4), using a glass Dounce homogenizer with
a glass pestle, followed by centrifugation at 1000g, 48C, for
10 min. The post-nuclear supernatants were directly used
for respiration and protein assays, as well as for the analysis
of citrate synthase (CS) activity. The post-nuclear super-
natants were analysed in a thermostatically controlled
oxygraphic chamber at 258C with continuous stirring (Oxy-
graph-2k, Oroboros Instruments, Innsbruck, Austria) as
previously described [20]. In brief, the samples were resus-
pended in 2 ml of mitochondrial respiration medium
(100 mM KCl, 40 mM sucrose, 10 mM TES, 5 mM MgCl2,
1 mM EGTA, 0.4% w/v fatty acid free-BSA (bovine serum
albumin), pH 7.2) and the protein concentration was deter-
mined (Bradford protein assay, Bio-Rad). Each respiration
assay was run with a constant amount of protein from one
wild-type and one knock-in mouse (0.3 mg for striatum,
0.6 mg from midbrain and cortex). The results were expressed
in nmol of O2/min mg
21 of total protein. The respiration rate
was recorded sequentially: (i) basal respiration in the presence
of complex I substrates (10 mM glutamate, 5 mM malate); (ii)
state 3 respiration with addition of 1 mM ADP; (iii) state 4 res-
piration with 1 mg ml21 oligomycin; and (iv) maximal
respiration rate was determined by progressive additions of
1.25 mM carbonyl cyanide m-chlorophenyl hydrazone
(CCCP). The respiratory reserve capacity was calculated asmaximal respiration2 basal respiration. Respiratory control
ratio or RCR was calculated as state 3/state 4.
4.7. Determination of citrate synthase activity
CS activity was determined using a colorimetric assay based
on the reaction between 5,50-dithiobis-(2-nitrobenzoic acid)
(DTNB) and CoA-SH to form 5-thio-2-nitrobenzoic acid
(TNB), which exhibits maximum absorbance at 412 nm,
according to the manufacturer’s instructions (Sigma,
CS0720). In brief, 20 ml of cold CelLytic M supplemented
with protease inhibitors (protease inhibitor cocktail,
Thermo Scientific 1861279) was added to 10 ml of post-
nuclear supernatant. The sample was homogenized and
centrifuged at 12 000g for 10 min. The supernatant was col-
lected, and protein concentration was determined by the
Bradford method (BioRad). Fifteen to 20 mg of protein was
added to a 200 ml reaction mixture containing 1 assay
buffer, 300 mM acetyl CoA and 100 mM DTNB. The reaction
was initiated by addition of oxaloacetate (OAA) to a final
concentration of 0.5 mM. CS activity was evaluated by fol-
lowing the absorbance of the reaction mixture at 412 nm
(SpectraMax M4) before and after addition of OAA every
10 s, for 2 min. Each sample was run in duplicate and CS
activity was expressed as units/min mg21 of total protein.
4.8. Dopamine HPLC analysis
Dopamine and its metabolite 3,4-dihydroxyphenylacetic acid
(DOPAC) concentrations were measured in the dorsal
striatum by reverse phase high-performance liquid chromato-
graphy coupled with electrochemical detection (Coulochem
III, Thermo Scientific) as described earlier [72]. Briefly,
18-month-old wild-type and ParkinS65A/S65A mice were
killed by cervical dislocation. Brains were quickly removed,
pre-commissural dorsal striatum was dissected on an ice-cold
Petri dish and freshly homogenized in 0.4 M percloric acid.
Following centrifugation and filtration of the supernatant,
dopamine and DOPAC were separated using a C18 reverse
phase column (Thermo Scientific). The mobile phase con-
sisted of 10% acetonitrile, 75 mM NaH2PO4.H2O, 0.17 mM
octanesulfonic acid, 2.5 mM triethylamine and 25 mM
EDTA, adjusted to pH 3.0 with orthophosphoric acid, and
was delivered at a flow rate of 0.6 ml min21. Protein levels
were determined by Lowry assay from pellets of the hom-
ogenates and catecholamine concentrations are expressed
per milligram protein.
4.9. Antibodies for biochemical studies
The following primary antibodies were used: total Parkin
immunoblotting (sc32282, Santa Cruz), mouse Parkin immu-
noprecipitation (in-house, S328D, 5th bleed), bI-tubulin
(Sigma), b-actin (Sigma), Calbindin (c9848Sigma), GAPDH
(Santa Cruz), CISD1 (Proteintech), NeuN (MAB377, Milli-
pore), PINK1 immunoblotting (BC100-494, Novus), PINK1
immunoprecipitation (in-house S085D, 3rd bleed), Mitofusin2
(MFN2) (in-house, S781D, 4th bleed), OPA-1 (#612607, BD
Biosciences), RHOT2 (Miro2) (H00089941, Abnova), COX IV
(#4850, Cell signalling technology), PDH (#2784, Cell signal-
ling technology), Tyrosine Hydroxylase (ab112, Abcam),
VDAC1 (ab15895, Abcam), Vinculin (#4650, Cell signalling
technology). Horseradish-peroxidase (HRP)-conjugated
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pho-Ser65 rabbit monoclonal antibody was raised by
Abcam in collaboration with the Michael J. Fox Foundation
for Research. Anti-phospho-Ser65-ubiquitin rabbit polyclonal
antibodies were generated by 21st Century Biochemicals Inc.
(Marlborough, MA, USA) using two phosphorylated
peptides, C-Ahx-YNIQKE[pS]TLHLVL-amide and Ac-YNIQ-
KE[pS]TLHLVL-Ahx-C-amide, that correspond to amino
acid residues 59–71 of ubiquitin. Antibodies were affinity
purified using phosphorylated and non-phosphorylated ver-
sions of the peptide immunogen (electronic supplementary
material, figure S9a). A fragment of human Miro1 fusion
protein encompassing residues 1–592 with N-terminal His-
SUMO tag was used as an immunogen to raise a sheep
polyclonal anti-Miro1 antibody (S531D). Antibodies were
affinity purified from antisera and characterized indicating
cross-reactivity with Miro1/2 as described in the electronic
supplementary material, figure S9b.
4.10. Tissue culture: proliferating and primary cells
Flp-In T-Rex HeLa stable cell lines were cultured in DMEM
(Dulbecco’s modified Eagle’s medium) supplemented with
10% FBS (fetal bovine serum), 2 mM L-glutamine, 1 penicil-
lin/streptomycin 1 non-essential amino acids (Life
Technologies), 15 mg ml21 of blasticidin and 100 mg ml21 of
hygromycin. Cell transfections of untagged wild-type or
mutant Parkin were performed using polyethylene method
[73]. Cultures were induced to express protein by addition
of 0.1 mg ml21 of doxycycline to the medium for 24 h. To
depolarize or uncouple mitochondrial membrane potential,
proliferating cells were treated with 10 mM antimycin
(Sigma) and 1 mM oligomycin dissolved in DMSO. Primary
mouse cortical neurons were isolated from the brains of
wild-type or mutant embryos of either sex at E16.5. Embryo-
nic cortices were collected in HBSS, and cells were dissociated
by incubation with trypsin-EDTA (#25300-054, Gibco) at
378C. Cells were then diluted in Neurobasal medium contain-
ing B27 supplement, Glutamax, penicillin/streptomycin and
plated at a density of 6.0  106 cells/well on 6-well plates
coated with 0.1 mg ml21 poly-L-lysine (PLL; Sigma). Neurons
were cultured at 378C in a humidified incubator with 5%
CO2. Every 7 days, the medium was replaced with fresh
medium containing B27. To depolarize or uncouple mito-
chondrial membrane potential in neurons, cultures were
treated with 10 mM antimycin (Sigma) and 1 mM oligomycin
dissolved in DMSO at 378C.
Primary lung fibroblasts were derived from adult mice as
previously described and maintained in DMEM/20%FBS/
penicillin–streptomycin at 378C/5% CO2 [26]. Primary
human skin fibroblast cultures at a low passage from the
patient and one matched control were established from a
minimally invasive skin biopsy sample according to routine
culture procedures. The cells were cultured in 5% CO2 and
90% humidity in high-glucose DMEM media (Gibco) sup-
plemented with 10% FBS (LSP #S-001-BR), 1 non-essential
amino acids, 1 mM sodium pyruvate, 100 Units/ml penicil-
lin, 100 mg ml21 streptomycin and 2 mM L-glutamine. The
retrovirus for analysis of mito-QC in human fibroblasts was
generated as previously described [52]. The cDNA for the
mito-QC reporter (mCherry, GFP and residues 101–152 of
human FIS1) was cloned into a pBABE.hygro vector or pBA-
BE.puro vector. The construct was co-transfected into 293FTcells with GAG/POL and VSV-G expression plasmids (Clon-
tech, Saint-Germain-en-Laye, France) for retrovirus
production using Lipofectamine 2000 (Life Technologies) in
accordance with the manufacturer’s instructions. Virus was
harvested 48 h after transfection and applied to cells in the
presence of 10 mg ml21 polybrene. Cells were selected with
either 500 mg ml21 hygromycin B or 2 mg ml21 puromycin.
Selected cells were seeded and incubated for 24 h into glass
bottom dishes (Ibidi m-Dish 35 mm) with media free of
sodium pyruvate and non-essential amino acids. Mitophagy
was stimulated for 24 h with 10 mM antimycin A (Sigma
#A8674) and 5 mM oligomycin A (Sigma #75251), and con-
trols were treated at equal volumes of DMSO. Cells were
fixed for 20 min with 3.7% PFA (Sigma #P6148) pH 7.0,
and subsequently washed twice with 2 ml of DMEM þ
10 mM HEPES pH 7.0 and incubated for at least 10 min.
Images were acquired using a ZEISS LSM 710 confocal micro-
scope and quantified using VOLOCITY 6.3 image analysis
software as previous described [39].
4.11. Tissue and cell lysis
For analysis of endogenous Parkin protein expression in vivo,
fresh brains were rapidly excised, placed in cold PBS and
microdissected with ultrafine microknives under stereomicro-
scopy. Upon isolation, each brain region was collected in a
single 1.5 ml microcentrifuge tube and immediately plunged
into dry ice. Tissue samples were stored at 2808C until ready
for processing. To make protein extracts, all tissues (neural
subregions and extra-neural tissues) were weighed and
defrosted on wet ice in fivefold mass excess of freshly pre-
pared, ice-cold lysis buffer containing: 50 mM Tris/HCl
pH 7.5, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 1%
Triton X-100, 0.25 M sucrose, 150 mM NaCl, 2 mM sodium
orthovanadate, 1 mM NaF, 10 mM sodium glycerolpho-
sphate, 1.15 mM sodium molybdate, 4 mM sodium tartrate
dehydrate, 100 mM 2-chloroacetamide, 1 mM DTT and com-
plete protease inhibitor cocktail (Roche). All inhibitors and
DTT were added immediately prior to use. Tissue homogen-
ization was performed using a probe sonicator at 48C
(Branson Instruments). Crude lysates were incubated at 48C
on wet ice for 30–45 min, before clarification by centrifu-
gation at 14 000 r.p.m. for 30 min at 48C. Supernatants used
for subsequent steps were carefully removed and either
used for downstream biochemical analyses or snap-frozen
and stored at 2808C.
Primary neurons or Hela cells were sonicated in lysis
buffer containing 50 mM Tris–HCl (pH 7.5), 1 mM EDTA,
1 mM EGTA, 1% (w/v) Triton, 1 mM sodium orthovanadate,
10 mM sodium glycerophosphate, 50 mM sodium fluoride,
10 mM sodium pyrophosphate, 0.25 M sucrose, 1 mM benza-
midine, 0.1 mM PMSF and protease inhibitor cocktail
(Roche). Following the sonication, lysates were incubated
for 30 min on ice. Samples were spun at 20 800g in an Eppen-
dorf 5417R centrifuge for 30 min. Supernatants were collected
and protein concentration was determined using the Brad-
ford kit (Pierce). Primary human skin fibroblasts were lysed
with ice-cold lysis buffer containing 50 mM Tris–HCl pH
7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium
orthovanadate, 50 mM sodium fluoride, 10 mM b-glycero-
phosphate, 5 mM sodium pyrophosphate, 0.1 mg ml21
microcystin-LR (Enzo Life Sciences), 270 mM sucrose, com-
plete EDTA-free protease inhibitor cocktail (Sigma Aldrich
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for 10 min at 48C. Supernatants were collected, quantified
by Bradford assay (Thermo Scientific) and subjected to
immunoblot analysis.
4.12. Membrane fraction enrichment
Cells were collected in ice-cold PBS containing 200 mM chlor-
oacetamide. They were then lysed in buffer containing
250 mM sucrose, 20 mM HEPES, 3 mM EDTA, 1% (w/v)
1 mM sodium orthovanadate, 10 mM sodium b-glyceropho-
sphate, 50 mM NaF, 5 mM sodium pyrophosphate, pH 7.5
and protease inhibitor cocktail (Roche) supplemented with
100 mM chloroacetamide at 48C. Cells were disrupted using
a glass hand-held homogenizer (40 passes) and the lysates
were clarified by centrifugation (800g at 48C for 10 min). The
supernatant was harvested and subjected to an additional cen-
trifugation step at 16 600g for 10 min at 48C. The resulting pellet
containing the mitochondrial-enriched fraction was resus-
pended in the above buffer containing 1% Triton X-100 and
centrifuged at 13 000 r.p.m. for 10 min at 48C. The super-
natant arising from this step contained solubilized
mitochondrial proteins.
4.13. Immunoblotting and immunoprecipitation
For immunoprecipitation of endogenous PINK1 from human
skin fibroblasts, 150 mg of whole-cell lysate was incubated
overnight at 48C with 5 mg of protein G pre-bound to
PINK1 antibody. The immunoprecipitations were washed
four times with lysis buffer containing 150 mM NaCl, then
twice with buffer containing 50 mM Tris–HCl pH 7.5,
0.1 mM EGTA, and eluted by resuspending in 20 ml of 1
SDS sample buffer. Denatured samples were subjected to
SDS-PAGE (4–12% Bis-Tris gels) and were transferred on to
Protran 0.2 NC nitrocellulose membranes (Amersham). Mem-
branes were blocked for 1 h at room temperature with 5%
non-fat milk (Marvel) or BSA in TBST (Tris-buffered saline
(50 mM Tris/HCl and 150 mM NaCl, pH 7.5) containing
0.1% Tween-20) in PBS pH 7.4 and incubated with the indi-
cated antibodies overnight at 48C with agitation. Detection
was performed using HRP-conjugated secondary antibodies
(Goat anti-Rabbit IgG (H þ L) Secondary Antibody, HRP
conjugate, #31460, Thermo Scientific; Rabbit anti-Mouse
IgG (H þ L) Secondary Antibody, HRP conjugate, #31450,
Thermo Scientific; Rabbit anti-Sheep IgG (H þ L) Secondary
Antibody, HRP conjugate, #31480, Thermo Scientific). Mem-
branes were developed using standard chemiluminescence
with ECL (Amersham) and exposure to hyperfilm (GE
Healthcare).
4.14. Activity-based profiling of Parkin
Transthiolation activity of Parkin activity in primary human
skin fibroblasts was measured as described previously [41].
Briefly, Parkin probe (produced by Dr. Satpal Virdee, MRC
PPU) was added to 50 mg of whole-cell lysate at a final
concentration of 5 mM. Reactions were incubated at 308C for
4 h and quenched by the addition of LDS sample buffer
with b-mercaptoethanol, before analysis via SDS-PAGE
(4–12% Bis-Tris Gels, Novex) and immunoblotting as
previously described.4.15. Ubiquitin enrichment
His-Halo-Ubiquilin UBA-domain tetramer (HALO-
UBAUBQLN1) was expressed in E. coli BL21 cells, affinity
purified on Ni-NTA-agarose and dialysed into 50 mM
HEPES pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM DTT
[11]. For ubiquitin capture, 200–400 mg of whole-cell extract
or 1 mg of membrane-enriched fraction was used for pull-
down with HALO-UBAUBQLN1 [11]. HALO-UBAUBQLN1 was
incubated with 200 ml of HaloLink resin (Promega) in bind-
ing buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.05%
NP-40) overnight at 48C under agitation [11]. HALO-TUBE
beads (20 ml) were added to lysates and incubated at 48C
for 4 h under agitation. Beads were washed three times
with lysis buffer containing 0.25M NaCl, and eluted by
resuspending in 20 ml of 1 LDS sample buffer containing
1 mM DTT.4.16. Protein purification, crystallization and structure
determination
Parkin S65N (ParkinS65N) (D84–143) was cloned into pET156P
vector (DU56345) and expressed as His-SUMO fusion in E.
coli BL21 cells, using conditions similar to those described in
Chaugule et al. [74]. His-tagged ParkinS65N was purified using
Ni-NTA resin. Protein eluted fromNi resinwas incubated over-
night at 48Cwith SENP1 protease to remove theHis-SUMO tag,
and dialysed in 20 mM Tris pH 7.5, 75 mM NaCl and 250 mM
TCEP buffer. Dialysed protein was further incubated with Ni-
NTA resin and tag-free ParkinS65N was collected in the flow
through, purified on Mono-Q and Superdex-75 columns (as
described in [64]) and concentrated to 8 mg ml21 for crystalliza-
tion. ParkinS65Nwas crystallized at 48C in 100 mMBIS-TRIS pH
5.5, 200 mM LiSO4 and 20% PEG3350 by using a vapour diffu-
sion method under sitting drop. Crystals were flash frozen in
20% glycerol, the native dataset was collected at ID30A-1 beam-
line, European SynchrotronRadiation Facility (ESRF,Grenoble).
Data were processed using Mosflm and Aimless in CCP4
(CCP4, 1994). ParkinS65N structure was determined by molecu-
lar replacement using Phaser in CCP4, WT-Parkin (pdb id:
5C1Z)was used as the searchmodel. The initial model obtained
from Phaser was further constructed and refined using Coot
[75] and REFMAC5 in CCP4 [76], respectively. The final
model of ParkinS65N shows excellent geometry (electronic
supplementary material, table S4).4.17. Human genetic analysis
4.17.1. Case 1 (S65N-M70)
Patient DNA samples were screened for variants using
HaloPlex targeted sequencing of 82 selected PD-associated
loci (Agilent Technologies, Santa Clara, CA, USA). DNA
was extracted from peripheral blood by standard procedures.
Sequencing was performed with a MiSeq sequencer (Illu-
mina, San Diego, CA, USA), variant calling with Genome
Analysis Toolkit [77] and the annotation with ANNOVAR
[78]. The variants were confirmed by independent DNA
sequencing method, Sanger sequencing. For the c.194G . A
mutation in PARK2 we used the following PCR and
sequencing primers for PCR and sequencing: 50-CTCGCA
TTTCATGTTTGACATTTCC; 50-ATGCTCCATGCAGACTG
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AATG. The frequency of variants was screened from ExAC
(http://exac.broadinstitute.org/) and gnomAD browsers
(http://gnomad.broadinstitute.org) [79], the potential patho-
genic effects were evaluated using CADD C-score [42] and
conservation using UniProt [80].
4.17.2. Case 2 (S65N-F60)
We downloaded the clinical data of case 2 (ID 3185) from the
Parkinson’s Progression Markers Initiative (PPMI) database
(www.ppmi-info.org/data) on 13 August 2018. PPMI is a
multi-centre, on-going longitudinal and observational study,
which contains clinical, imaging and biological data from
454 PD patients and 215 control patients currently stored at
the Laboratory of Neuro Imaging (LONI) database at Univer-
sity of California, Los Angles (UCLA). The cohort consists of
620 females and 828 males. The open-access repository is
available online after registration at http://www.ppmi-info.
org/. Informed consent was signed by the patients enrolled
in the PPMI study. The patient’s DNA whole-genome
sequence data were downloaded from PPMI repository on
8–11 September 2018 and we filtered all coding variants in
82 PD-associated loci (used in-targeted sequencing panel of
patient S65N-M70 (ID3185) excluding mitochondrial DNA)
with a CADD C-score of over 20 and a carrier frequency less
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